- Home
- SNY vs IOVA Comparison
SNY vs IOVA Comparison
Compare SNY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- IOVA
- Stock Information
- Founded
- SNY 1994
- IOVA 2007
- Country
- SNY France
- IOVA United States
- Employees
- SNY N/A
- IOVA N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNY Health Care
- IOVA Health Care
- Exchange
- SNY Nasdaq
- IOVA Nasdaq
- Market Cap
- SNY 113.4B
- IOVA 975.1M
- IPO Year
- SNY N/A
- IOVA N/A
- Fundamental
- Price
- SNY $47.26
- IOVA $2.25
- Analyst Decision
- SNY Buy
- IOVA Buy
- Analyst Count
- SNY 4
- IOVA 11
- Target Price
- SNY $61.50
- IOVA $11.90
- AVG Volume (30 Days)
- SNY 2.7M
- IOVA 9.5M
- Earning Date
- SNY 10-24-2025
- IOVA 11-06-2025
- Dividend Yield
- SNY 3.40%
- IOVA N/A
- EPS Growth
- SNY 118.56
- IOVA N/A
- EPS
- SNY 8.65
- IOVA N/A
- Revenue
- SNY $53,714,621,258.00
- IOVA $241,525,000.00
- Revenue This Year
- SNY $1.53
- IOVA $67.40
- Revenue Next Year
- SNY $7.06
- IOVA $56.32
- P/E Ratio
- SNY $5.43
- IOVA N/A
- Revenue Growth
- SNY 15.65
- IOVA 636.99
- 52 Week Low
- SNY $44.73
- IOVA $1.64
- 52 Week High
- SNY $60.12
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- SNY 44.98
- IOVA 45.99
- Support Level
- SNY $46.50
- IOVA $2.19
- Resistance Level
- SNY $47.33
- IOVA $2.38
- Average True Range (ATR)
- SNY 0.66
- IOVA 0.14
- MACD
- SNY -0.13
- IOVA -0.01
- Stochastic Oscillator
- SNY 41.48
- IOVA 40.82
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.